CTSI External Advisory Board

CTSI’s strategic direction is informed by an External Advisory Board (EAB), which is convened for a full-day meeting twice a year. Board members also assist with specific initiatives. For example, Sandra Hernández, MD, has helped to bring together major community and government groups involved in CTSI's crosscutting San Francisco Health Improvement Partnerships (SF HIP) program.

The External Advisory Board includes representation from academia, the pharmaceutical industry, venture capital, and foundations.


  • Warren S. Browner, MD, MPH, CEO, California Pacific Medical Center;
  • Garret Fitzgerald, MD, Director, Institute for Translational Medicine and Therapeutics, U. Penn.;
  • Victoria Hale, PhD, Founder and Former CEO, One World Health; current CEO, Medicines360;
  • Sandra R. Hernández, MD, President and CEO, California HealthCare Foundation;
  • David W. Martin, Jr., MD, Chairman and Chief Executive Officer of AvidBiotics;
  • Mark D. Smith, MD, MBA, former President and CEO, California HealthCare Foundation.

See complete bios below:

Warren S. Browner, MD, MPH
Vice President Academic Affairs and Scientific Director of the Research Institute at
California Pacific Medical Center

Dr. Browner’s current research focuses on the genetics of human longevity.  Dr. Browner is a graduate of Harvard College, received an MD from the University of California, San Francisco, and an MPH from the University of California, Berkeley. He completed his residency in internal medicine and was a Mellon Scholar in Clinical Epidemiology at UCSF. He was on the full-time faculty at UCSF for 15 years, serving as Chief of General Internal Medicine and Acting Chief of the Medical Service at the San Francisco VA Medical Center; he is currently Adjunct Professor of Medicine and Epidemiology & Biostatistics. He also served as the Executive Editor of the American Journal of Medicine and as a Research Associate for the National Bureau of Economic Research (Program on Health Care). He is currently a member of the VA’ s national Cooperative Studies Monitoring and Review Board. He has published more than 120 peer-reviewed original research articles, is the author of Publishing and Presenting Clinical Research, and is co-author of Designing Clinical Research: An Epidemiologic Approach.

As Scientific Director, he is responsible for all aspects of research at CPMC, including strategic direction, recruiting, and infrastructure.  Dr. Browner oversees Institutional Review Board, Institutional Animal Care and Utilization Committee, Biosafety Committee, Embryonic Stem Cell Research Oversight Committee, and Conflict of Interest Committee.  He directs all activities in Graduate Medical Education (GME), including CPMC-sponsored training programs in internal medicine, ophthalmology, psychiatry, radiation oncology, cardiology, gastroenterology, pulmonary/critical care medicine, and hand surgery.  He also supervises activities of the Institute for Health and Healing (IHH), the Centers for Research in Clinical Excellence (a medical center program that provides start-up funding to encourage clinical researchers), the program in ethics, and the Health Sciences Library.

Garret A. FitzGerald, MD
Professor, University of Pennsylvania

Garret A. FitzGerald, MD, is the McNeil Professor in Translational Medicine and Therapeutics at the University of Pennsylvania in Philadelphia, where he chairs the Department of Pharmacology and directs the Institute for Translational Medicine and Therapeutics (www.itmat.upenn.edu).

His work is focused on the translational therapeutics of the arachidonic acid cascade and the role of peripheral molecular clocks in metabolic and cardiovascular function. ITMAT has grown to over 800 members and supports research programs, faculty recruitment, education and infrastructural developments relevant to translational research.

Dr. FitzGerald serves as Chair of the Department of Pharmacology at Penn. The Department ranks #1 in NIH funding in the US and supports a Graduate Group with roughly 90 students. He also serves on the Peer Review Advisory Committee of the NIH, the Science Board of the FDA and the Drug Forum of the Institute of Medicine.

Victoria G. Hale, PhD
Founder and CEO, One World Health

Dr. Hale is the CEO of Medicines360, a non-profit pharmaceutical company that addresses unmet needs of women by developing innovative, affordable and sustainable medical solutions. She is also the founder and former CEO of OneWorld Health, the first nonprofit pharmaceutical company in the U.S. Dr. Hale was named as an Ashoka Fellow in 2006, a select group of leading social entrepreneurs who drive innovative and uncommon solutions and transformative social change work. In 2005 Dr. Hale and OneWorld Health were recognized with The Economist Innovation Award for Social and Economic Innovation, to highlight the importance of individual thinking and innovation in the business world. OneWorld Health was awarded the "Social Responsibility Award" at the 2005 Pharmaceutical Achievement Awards, and Dr. Hale and OneWorld Health were included in the Scientific American 50, the magazine’s annual list recognizing outstanding acts of leadership in science and technology (2004). She was also named one of 2004's “Most Outstanding Social Entrepreneurs” by the Schwab Foundation for Social Entrepreneurship in Switzerland. Dr. Hale established her expertise in all stages of biopharmaceutical drug development at the US Food and Drug Administration (FDA), Center for Drug Evaluation and Research and later at Genentech, Inc., the world's first biotechnology company. Dr. Hale earned her Ph.D. in Pharmaceutical Chemistry from UCSF.

Sandra R. Hernández, MD

President and CEO, California HealthCare Foundation

Dr. Hernández is a graduate of Yale University, Tufts School of Medicine, and the John F. Kennedy School of Government at Harvard University. She is President and CEO of the California HealthCare Foundation, an independent philanthropy with assets of $800 million, headquartered in Oakland, California and dedicated to improving the health of the people of California through its three program areas; Innovations For The Underserved, Better Chronic Disease Care, and Market and Policy Monitor.

She was formerly CEO of the San Francisco Foundation, and served as the Director of Public Health for the City and County of San Francisco. She is an assistant clinical professor at UCSF School of Medicine and maintains an active clinical practice at San Francisco General Hospital in the AIDS clinic.

Dr. Hernández currently serves on the boards of the Council on Foundations, Lucile Packard Children's Hospital, and Corporation for Supportive Housing. She is also a trustee of the Western Asbestos Settlement Trust.

Her prior affiliations include President Clinton's Advisory Commission on Consumer Protection and Quality in the Healthcare Industry; The Pew Commission on Environmental Health; The Foundation Consortium for California’s Children and Youth; Grantmakers in Health; American Foundation for AIDS Research (amfAR); the Volunteerism Project; Stern Grove Festival Association; the Institute of Medicine's Committee on the Consequences of Uninsurance; the National Alliance for Hispanic Health; Harvard's John F. Kennedy School of Government Executive Session on Philanthropy; Blackbaud, Inc., a leading provider of software and online services for the nonprofit community; the Latino Community Foundation, a supporting organization of The San Francisco Foundation; and the California Managed Risk Medical Insurance Board, which is the governing body for California's Children's Health Insurance Program. 

David W. Martin, Jr., MD
Chairman and Chief Executive Officer of Avid Biotics

Previously, Dr. Martin was Chairman and CEO of GangaGen, Inc., and he was a founder and CEO of Eos Biotechnology, which merged with Protein Design Labs in April 2003. He has been SVP of R&D at Genentech (1982-1990), Executive VP of R&D at DuPont Merck (1991-1993), and President of Chiron Therapeutics (1994-1995). He currently serves as lead director of the Boards of Varian Medical Systems, Inc., Palo Alto, and Cubist Pharmaceuticals, Inc., Lexington, MA, and he is a member of the California Counsel on Science and Technology and chairman of BayBio. Prior to joining Genentech in 1982, he was Professor of Medicine and Biochemistry at UCSF and Investigator, Howard Hughes Medical Institute.

Mark D. Smith, MD, MBA
Former President and CEO, California HealthCare Foundation

Dr. Smith is the former President and CEO of the California HealthCare Foundation. A board-certified internist, he is a member of the clinical faculty at the University of California San Francisco and an attending physician at the Positive Health Program for AIDS care at San Francisco General Hospital. He is a member of the Institute of Medicine and serves on the board of the National Business Group on Health.

Prior to his work at CHCF, Dr. Smith was Executive Vice President of the Henry J. Kaiser Family Foundation and served as Associate Director of the AIDS Service and Assistant Professor of Medicine and of Health Policy and Management at Johns Hopkins University. He has served on the Performance Measurement Committee of the National Committee for Quality Assurance and the editorial board of the Annals of Internal Medicine.

Dr. Smith received a B.A. in Afro-American Studies from Harvard College, an M.D. from the School of Medicine at the University of North Carolina at Chapel Hill, and an M.B.A. with a concentration in health care administration from the Wharton School at the University of Pennsylvania.